JP Morgan Maintains Neutral on BioCryst Pharma, Raises Price Target to $13

Benzinga · 3d ago
JP Morgan analyst Jessica Fye maintains BioCryst Pharma (NASDAQ:BCRX) with a Neutral and raises the price target from $12 to $13.